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range¼0.09-9.01yrs] had a signiﬁcant impact on OS [p<0.01]
and EFS [p<0.01]. Notably, treatment with any chemo-
therapy prior to receiving a DLI did not signiﬁcantly impact
OS [p¼0.22] or EFS [p¼0.54].
Our analysis reveals no difference in OS or EFS between the
use of fresh or cryopreserved cells for DLI. There is a trend to
favor fresh cell DLI in patients who have undergone a non-
myeloablative transplant. Our study conﬁrmed previous
observations that a greater interval between original trans-
plant and relapse correlates with greater DLI success.We also
highlight that in the setting of relapsed disease, pretreat-
ment with chemotherapy did not impact post-DLI OS or EFS.
In conclusion, selected patients can achieve long term sur-
vival with DLI for post-transplant relapse though the overall
outcomes remain dismal.Figure 1. Time to transplant from preliminary search
Figure 2. Cumulative incidence probability of transplant with an adult unre-
lated donor with CBU transplant as a competing risk415
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African American (AFA) patients are an underserved race
group in bone marrow transplant due to their diverse HLA,
limited number of potential unrelated donors (URD) and low
URD availability rates. Newly entered AFA patients who had
Be The Match Registry searches of intermediate difﬁculty
were enrolled in this blind randomized study to determine if
proactive URD contact and HLA typing would (1) increase
patient transplant rates (2) increase selection of an URD over
a cord blood unit (CBU).
We examined incoming patients from Feb to Oct of 2013 to
identify and enroll a subset of AFA searches who had 10
potential 8/8 URD with HapLogic allele matching prediction
of 31% or zero 8/8 with 10 7/8 URD with matching pre-
diction of 76%. Searches were randomized 1:1 into two
arms; 182 to intervention and 178 to no intervention. In the
intervention arm, HLA specialists reviewed 182 patient
searches and selected 2473 URD for contact to conﬁrm
availability with 591 available URD HLA typed (up to 20 URD/
patient). Patient searches were excluded from the study if
they had “unproductive”URD search results (i.e. no URDwith
at least a 2% chance of being 7/8) or had “very productive”
URD search results (i.e. 11 URD with 31% prediction of
being an 8/8 or zero potential 8/8 URD with 10 URD with
75% prediction of being a 7/8). URD were high-resolution
typed at HLA-A, B, C, DRB1 and DQB1, and the transplant
center was notiﬁed when an available 7/8 or better matched
URD was identiﬁed for consideration. Patient cases were
followed for URD or CBU transplant endpoints up to 1 year
post initial search submission.
Descriptive statistics for the two randomized arms were
similar in patient age, disease (malignant vs non-malignant),
and URD search productivity. 217matched and available URD
notiﬁcations were sent to transplant centers on behalf of 115
patients. Although not achieving statistical signiﬁcance,
intervention patients progressed to transplant 20% of the
time vs. 15% in the non-intervention group at 1 year (Figure
1) and transplanted more oftenwith an URD over a CBU, 63%
vs. 48%, respectively. At 1 year, the intervention group pro-
gressed to URD transplant in 12% of cases compared to 7% in
the non-intervention group (Figure 2) and CBU transplant in
7% of intervention cases vs. 8% in the non-intervention group.AFA searches not meeting the inclusion criteria for study
randomization were also examined. Very productive poten-
tial 8/8 URD searches resulted in transplant 27% of the time
(88% chose an URD) and searches containing zero 8/8 URD
with many potential 7/8 URD resulted in transplant 19% of
the time (44% chose an URD). Patients that had zero potential
7/8 donors with at least 2% likelihood to match only went to
transplant 2% of the time.
Additional registry URD contact and HLA typing efforts for
challenging AFA patient searches may clarify the search op-
tions available and assist transplant decision making.416
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Aim: Infection is the leading cause of non-relapse mortality
(NRM) in allo-HSCT. A community respiratory virus infection
(RVI) screening programwas instituted at our center from 5/
2010 in order to prevent nosocomial infection, assist in
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S293cohorting strategies and minimize RV during allo-HSCT. The
impact of RVI screening on respiratory-related NRM was
assessed.
Method: Consecutive allo-HSCT patients (pts) experiencing
NRM between 1/00 e 1/14 were identiﬁed from a prospec-
tively maintained database. NRM episodes were assessed
pre- and post-RVI screening and an etiology assigned
following medical record review and treating physician
determination. RVI were identiﬁed in symptomatic pts from
nasal/pharyngeal swabs or bronchoalveloar lavage speci-
mens using PCR or immunoﬂuorescence.
Results: 204 allo-HSCT were evaluated, 118 pre- and 86 post-
RVI screening. For the entire cohort: male:female ratio was
1.4:1, median age 52 (17-71) years, median follow up 24.2
(2.4-154) months. Most common pre-HSCT diagnoses were
myeloid malignancies (43%), NHL (22%) ALL (12%). 3 year DFS
and OS was 50.7% and 59.6%. There were no signiﬁcant dif-
ferences between study cohorts. There was a signiﬁcant
difference between pre-RV and post-RV cohorts in condi-
tioning intensity (MA 46% vs 19%, NMA 53% vs 81%, p<0.01),
donor source (MS 71% vs 29%, MUD 0 vs 44%, p<0.01) and
TBI-based conditioning (20% vs 51%, p<0.01) reﬂecting
changes in departmental practice. Most common RVI’s were
rhinovirus (40%), RSV (30%), parainﬂuenza (20%) and coro-
navirus (10%).
Overall NRM was 24.5%.Pre- and post-RVI screening NRM
was 22.9% and 26.7% (p¼0.53). 12/26 (46%) NRM events were
respiratory-related pre-RVI vs 6/24 (25%) post-RVI (RR 0.54,
95%CI 0.24-1.22, p¼0.14). Post-RVI screening, viral pneumo-
nitis was the cause of respiratory death in 2/5 pts (1¼RSV,
1¼rhinovirus).
Conclusion: Respiratory-related deaths represent a signiﬁ-
cant NRM burden post allo-HSCT. RVI screening may impact
on respiratory-related NRM in allo-HSCT.417
Graft Versus Host Disease Prophylaxis with a Bortezomib-
Based Regimen without G-CSF Support for Patients
Undergoing MUD Transplant: Evaluation of Engraftment
Kinetics and Transplant Outcomes
Antonio M. Jimenez 1, Alfonso D. Moreno 2,
John Maciejewski 3, Andrew Dalovisio 4, Deborah Katz 4,
Christina Havey 2, Nazneen Merchant 2, Henry C. Fung 5,
Sunita Nathan 2. 1 Rush University Medical Center, Chicago, IL;
2 Section of Bone Marrow Transplant and Cell Therapy, Rush
University Medical Center, Chicago, IL; 3 Section of Bone
Marrow Transplantation and Cell Therapy, Rush University
Medical Center, Chicago, IL; 4Hematology Oncology and Cell
Therapy, Rush University Medical Center, Chicago, IL; 5 Bone
Marrow Transplant Program, Temple University Hospital/Fox
Chase Cancer Center, Philadelphia, PA
Background: The proteasome inhibitor Bortezomib has been
successfully used to prevent the development of graft-
versus-host disease (GVHD) in recipients of matched unre-
lated donor (MUD) or mismatch related donor (mMRD)
allogeneic HSCT. We sought to evaluate the efﬁcacy of this
agent in our patient population and assess its impact on
neutrophil engraftment when G-CSF support was not
routinely utilized.
Methods: We conducted a retrospective review of patients
(pts) with hematologic malignancies who underwent MUD
allogeneic HSCT at our institution and received GVHD pro-
phylaxis with bortezomib (dose 1.3 mg/m2) administered on
days +1, +4, and +7 after stem cell infusion, in addition to
standard prophylaxis with tacrolimus and methotrexate.
Since our ﬁrst treated patient developed hyper-acute GVHD,standard G-CSF support was omitted and reserved only for
pts with severe sepsis or delayed engraftment.
Results: Twenty-one MUD recipients receiving bortezomib-
based GVHD prophylaxis were transplanted at our institution
between 2012 and 2014. Median age was 51 years (range:
34-62 yrs); male to female ratio 2:1. Indications for trans-
plantation included: AML (11/52.4%), ALL (6/28.6%), MPN (2/
9.5%) CLL (1/4.8%) and NHL(1/4.8%). Graft source was mobi-
lized peripheral blood stem cells for all pts. Seven pts (33.3%)
received a myeloablative conditioning regimen, whereas 14
pts (66.7%) received a reduced-intensity regimen. Median
donor chimerism at days +30 and +100 was 98.5% (range 70-
99%) and 98% (range 81-99%) respectively. Median time for
neutrophil engraftment was 14.38 days +/- 1.86. Cumulative
incidence of grade III-IV aGVHD at day +100 was 14.3%. Non-
relapse mortality (NRM) at day +100 was 9.5% and the
cumulative incidence of relapse was 4.8% at day +180 and
19% at 1 year.
Conclusions: Bortezomib-based GVHD prophylaxis resulted
in acceptable rates of acute GVHD and non-relapsemortality;
our results are encouraging and similar to those available in
the current literature. The use of bortezomib did not result in
delayed engraftment or graft failure (when compared to
historical controls) even when standard growth factor sup-
port was omitted in patients undergoing MUD transplant.418
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Prognosis after allogeneic hematopoietic stem cell trans-
plantation (SCT) in patients with relapsed or refractory he-
matologic malignancies at the time of SCT is poor due to the
increased risk of relapse or TRM. Several intensiﬁed condi-
tioning regimens have been reported, however, long term
outcome after 5 years was not clariﬁed. This study is aimed to
evaluate the long term outcome of SCT with intensiﬁed
conventional myeloablative conditioning regimen.
We retrospectively analyzed a total of 59 adult patients with
advanced hematologic malignancies including refractory
AML(n¼32), CML with blastic crisis (n¼14), refractory ALL
(n¼8) and others (n¼5) who received allogeneic SCT with
intensiﬁed myeloablative conditioning regimen of busulfan
(BU) 8mg/kg + cyclophosphamide 120mg/kg + TBI 10Gy
(n¼20), melphalan (MEL) 180mg/m2 + BU 8mg/kg + TBI 10Gy
(n¼32) or MEL180 mg/m2+ TBI 10Gy (n¼7) from January
1994 to December 2003 in our institution. GVHD prophylaxis
consisted with tacrolimus or cyclosporine and short courses
of methotrexate.
The median follow-up of the surviving patients was 8.3 years
(0.1-18.8). Median age at transplant was 36 (17-54). Fifty-one
patients received BM, 4 received PBSC, 1 received both and 3
received CB; 18 from a matched related donor, 15 from a
matched unrelated donor, 7 from a mismatched related
donor and 19 from a mismatched unrelated donor. Rejection
was observed in only 1 patient. A total of 44.6% and 23.2% of
evaluable patients had grade II-IV and grade III-IV acute
GVHD, respectively and 57.9% of evaluable patients experi-
enced extensive chronic GVHD. Overall survival and disease-
free survival at 5 years was 31.5% and 29.7%, whereas that at
